CYCLOSERINE

Search structure


Trade Names:	SEROMYCIN
Synonyms:	Cycloserine Cycloserinum D-cycloserine NSC-154851 NSC-76029 Orientomycin Seromycin
Status:	Approved (1964)
Entry Type:	Small molecule
Molecule Category:	UNKNOWN
ATC:	J04AB01
UNII:	95IK5KI84Z


InChI Key	DYDCUQKUCUHJBH-UWTATZPHSA-N
Smile	N[C@@H]1CONC1=O
InChI	InChI=1S/C3H6N2O2/c4-2-1-7-5-3(2)6/h2H,1,4H2,(H,5,6)/t2-/m1/s1

Action	Mechanism of Action	Reference
INHIBITOR	Alanine racemase inhibitor	ISBN PubMed

Targets	EC50(nM)	IC50(nM)	Kd(nM)	Ki(nM)	Inhibition(%)
Enzyme Isomerase	-	-	-	-	10
Ion channel Ligand-gated ion channel Ionotropic glutamate receptor NMDA receptor	18100	2300	-	-	-

Mesh Heading	Maximum Phase	Mesh ID	Reference
Asperger Syndrome	3	D020817	ClinicalTrials
Phobia, Social	3	D000072861	ClinicalTrials
Stress Disorders, Post-Traumatic	3	D013313	ClinicalTrials
Schizophrenia	3	D012559	ClinicalTrials
Panic Disorder	3	D016584	ClinicalTrials
Phobic Disorders	3	D010698	ClinicalTrials
Obsessive-Compulsive Disorder	3	D009771	ClinicalTrials
Autistic Disorder	3	D001321	ClinicalTrials
Pain	3	D010146	ClinicalTrials
Smoking Cessation	3	D016540	ClinicalTrials
Bipolar Disorder	2	D001714	ClinicalTrials
Cocaine-Related Disorders	2	D019970	ClinicalTrials
Stroke	2	D020521	ClinicalTrials
Tobacco Use Disorder	2	D014029	ClinicalTrials
Alcohol Drinking	2	D000428	ClinicalTrials
Substance-Related Disorders	2	D019966	ClinicalTrials
Psychotic Disorders	2	D011618	ClinicalTrials
Opioid-Related Disorders	2	D009293	ClinicalTrials
Agoraphobia	2	D000379	ClinicalTrials
Low Back Pain	2	D017116	ClinicalTrials
Depressive Disorder, Major	2	D003865	ClinicalTrials
Brain Injuries	2	D001930	ClinicalTrials
Sleep Apnea Syndromes	1	D012891	ClinicalTrials
Anxiety	1	D001007	ClinicalTrials
Pulmonary Disease, Chronic Obstructive	0	D029424	ClinicalTrials
Osteomyelitis	0	D010019	ClinicalTrials
Tourette Syndrome	0	D005879	ClinicalTrials

System Organ Classification (SOC)

	Relative Frequency (%)
Psychiatric disorders	37.5
Nervous system disorders	25.0
Injury, poisoning and procedural complications	9.38
General disorders and administration site conditions	6.25
Metabolism and nutrition disorders	6.25
Musculoskeletal and connective tissue disorders	6.25
Hepatobiliary disorders	3.12
Immune system disorders	3.12
Skin and subcutaneous tissue disorders	3.12

CONTENTS


Active Pharmaceutical Ingredients (APIs) Scaffolds	Exact Similarity SubStructure	Threshold (%) >= 70